Vitamin D₃, traditionally recognized for its role in calcium metabolism, exerts multi-dimensional effects on immune regulation, inflammatory buffering, and skeletal integrity.

Evidence demonstrates that suboptimal serum vitamin D status correlates with increased risk and severity of rheumatoid arthritis (RA) and osteoarthritis (OA).

A physiological dosage of 10 μg/day (400 IU), as included in Keyora JointOra 5 in 1, provides a clinically validated, safe, and long-term support level for immune tolerance restoration, cytokine downregulation, and bone protection.

Mechanistically, vitamin D₃ enhances regulatory T cell (Treg) function, suppresses pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), inhibits NF-κB signaling, and maintains calcium-phosphorus balance.

When co-formulated with UC-II®, Omega-3 fatty acids, Glucosamine, Chondroitin Sulfate, and Hyaluronic Acid, vitamin D₃ amplifies multi-target synergy - bridging immune modulation, inflammation suppression, and structural repair.

Clinical guidelines (EULAR, ESCEO, EFSA) and randomized trials consistently support its efficacy in reducing inflammatory markers (CRP, DAS28, IL-6) and improving joint function (WOMAC).

Target populations include RA/OA patients, postmenopausal women with declining bone density, sedentary individuals with low sun exposure, and those requiring long-term multi-nutrient support.

Thus, vitamin D₃ at 10 μg/day serves as a foundational immune-metabolic modulator within integrated joint health strategies.